Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Healthcare partners in Widnes have been nationally recognised for their outstanding efforts. The collaboration, including local healthcare organisations and global biopharmaceutical company Boehringer ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

While it can affect your body differently when you have diabetes, sugar doesn’t have to be completely off the table.

The KidneyMobile is back in Peoria to raise awareness about kidney diseases. March is National Kidney Month. Representatives ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...